Category: Q&A

Q&A with Dr. Sergio Rutella: Multi-analyte studies in acute myeloid leukemia

Sergio Rutella, M.D., Ph.D. FRCPath is a Professor of Cancer Immunotherapy at the John van Geest Cancer Research Centre at Nottingham Trent University. His research focuses on acute myeloid leukemia (AML), an aggressive form of cancer that originates in the...

/ December 14, 2017

Q&A with Dr. David Coffey, FHCRC: Multi-analyte studies in multiple myeloma and lymphoma

David Coffey, MD, is a physician scientist with the Fred Hutchinson Cancer Research Center in Seattle, Washington. When he’s not treating patients, he’s in the lab researching blood cancers such as multiple myeloma and lymphoma. His research centers on the...

/ November 16, 2017

Multi-Analyte Analysis of Lung Cancer FFPE Samples with 3D Biology™ Technology

NanoString sat down with McGarry Houghton, M.D., Associate Member of the Clinical Research and Human Biology Divisions at Fred Hutch Cancer Research Center, to discuss how his lab is using 3D Biology™ Technology to advance understanding of the lung tumor...

/ June 1, 2017

Characterizing Severe Autoimmune Toxicities Associated with Checkpoint Inhibitor Therapies

Immune checkpoint inhibitors (ICI) have emerged as powerful tools against cancer but in some cases have caused inflammation of organ systems that contributed to morbidity or mortality in patients. The molecular underpinnings of toxicities from immune checkpoint inhibitors are not...

/ March 31, 2017

Monitoring Clinically Actionable Proteins- A Q&A with Gordon Mills, MD Anderson Cancer Center

NanoString sat down with Gordon Mills, M.D., Ph.D., Chair of Systems Biology Department at MD Anderson Cancer Center in Houston and lead developer of The Cancer Proteome Atlas (TCPA), to talk about the value of cataloging proteins and the future...

/ March 20, 2017